GlobeNewsWire
30 May 2026, 15:15 UTC · 15w ago
Verdict
Headline takes no side. We score MLYS +1.00 across four claims — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Lorundrostat demonstrated statistically significant and clinically meaningful blood pressure reductions in Phase 3 Launch-HTN trial participants with chronic kidney disease (CKD).
More positive than 91% of claims this week
Lorundrostat achieved a 52.2% placebo-adjusted reduction in urinary albumin-to-creatinine ratio (UACR) among CKD participants with albuminuria.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 85% of claims this week
The drug showed a favorable safety profile with low rates of confirmed hyperkalemia (2.4% in CKD participants and 0% in non-CKD participants).
More positive than 77% of claims this week
The U.S. FDA has a PDUFA target date of December 22, 2026, for the review of lorundrostat.
More positive than 65% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company presented positive Phase 3 clinical data showing statistically significant reductions in blood pressure and kidney markers for its lead drug candidate.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
20h ago
−9.0%
Price is moving against the score
$28.66 vs $31.50 close before publication (May 29) · not market-adjusted
MLYS chart →
